Does anti-HBV therapy benefit the prognosis of HBV-related hepatocellular carcinoma following hepatectomy?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24121884.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Hepatitis B virus (HBV) is an important etiological factor for hepatocarcinogenesis, because HBV DNA load and HBV reactivation are major risks that influence the long-term survival of hepatocellular carcinoma (HCC) patients who underwent hepatectomy and, thus, may cause postoperative liver function deterioration, tumor recurrence, and reduce patient's overall survival. However, anti-HBV therapy can suppress HBV replication, improve the remnant liver function, render patients better able to tolerate HCC treatments, and may even improve their prognosis. In this paper, an anti-HBV therapy that benefits the prognosis of HBV-related HCC following hepatectomy is reviewed.
Medical subject headings
- Antiviral Agents
- Carcinoma, Hepatocellular
- Hepatectomy
- Liver Neoplasms